Business
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, as part of a poster at IMMUNOLOGY2026, the annual meeting of the American Association of Immunologists (AAI) taking place in Boston, Massachusetts, April 15-19, 2026. Poster Presentation Details: Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein that Induces Selective Expansion of Functional, Stable FOXP3+ Tregs for the Treatment of AutoimmunityPresenter: Natasha M. Girgis, Director, Translational PharmacologyDate and Time: Saturday, April 18, 2026, 11:30 a.m. – 12:30 p.m. EDTPoster Number: 733 Session: Therapeutics for Autoimmune Diseases IILocation: Exhibit HallAs part of the presentation, Dr. Girgis will discuss new in vivo data that supports CUE-401’s ability to induce FOXP3+ antigen-specific induced T regulatory cells (iTregs) from FOXP3- conventional CD4+ T cells through the coordinated delivery of TGF-β and interleukin-2 (IL-2) signals. This new and promising preclinical data supports CUE-401’s therapeutic potential to restore immune homeostasis in autoimmune and inflammatory diseases. About CUE-401CUE-401 is a novel bifunctional therapeutic that incorporates an innovative TGF-beta breathing-mask moiety with Cue Biopharma’s clinically validated interleukin-2 (IL-2) mutein in a single injectable biologic. The design of CUE 401 was inspired by Nobel Prize winning science in 2025 for the role of IL-2 and TGF-beta as essential components in helping establish immune tolerance by regulating FOXP3 signaling. CUE-401 is designed to promote immune regulation and tolerance by three complementary mechanisms: 1. Direct regulation of proinflammatory mechanisms by TGF-beta, 2. Expansion of existing Tregs by IL-2, and 3. Conversion of FOXP3- conventional CD4+ T cells into FOXP3+ induced Tregs through the coordinated provision of TGF-beta and IL-2 signals, both of which are required for the de novo induction of FOXP3 expression. About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is deve...